Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SHR-1701 |
| Trade Name | |
| Synonyms | SHR 1701|SHR1701|Retlirafusp Alfa |
| Drug Descriptions |
SHR-1701 is a monoclonal anti-PD-L1 antibody fused to the extracellular domain of Tgfbr2, which may trap TGFbeta and block TGFbeta-mediated immune suppression, leading to enhanced response to PD-L1 inhibition (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 9055-9055). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1 Inhibitor 15 TGFB inhibitor 5 |
| CAS Registry Number | 2395839-91-3 |
| NCIT ID | C178398 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Famitinib + SHR-1701 | Famitinib SHR-1701 | 0 | 0 |
| SHR-1701 | SHR-1701 | 0 | 1 |